PFIZER INC Revenue
PFIZER INC (PFE) reported Revenue of $15.03 billion for the 3-month period ending 2026-06-28, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement
us-gaap:Revenues · last filed 2026-08-04
- PFIZER INC revenues for the quarter ending 2026-06-28 was $15.03B, a 2.60% increase year-over-year.
- PFIZER INC revenues for the quarter ending 2026-03-29 was $14.45B, a 5.37% increase year-over-year.
- PFIZER INC revenues for the quarter ending 2025-12-31 was $17.56B, a 1.16% decline year-over-year.
- PFIZER INC revenues for the quarter ending 2025-09-28 was $16.65B, a 5.92% decline year-over-year.
- PFIZER INC revenues for fiscal 2025 was $62.58B, a 1.65% decline from fiscal 2024.
- PFIZER INC revenues for fiscal 2024 was $63.63B, a 6.84% increase from fiscal 2023.
- PFIZER INC revenues for fiscal 2023 was $59.55B, a 41.14% decline from fiscal 2022.
- PFIZER INC revenues for fiscal 2022 was $101.17B, a 24.46% increase from fiscal 2021.
| Period end | Revenues 3 month | Revenues 3 month as first filed | Revenues 6 month | Revenues 6 month as first filed | Revenues 9 month | Revenues 9 month as first filed | Revenues 12 month | Revenues 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-28 | $15.03B 10-Q · filed 2026-08-04 | $29.48B 10-Q · filed 2026-08-04 | $47.04B derived: sum of 3 quarters · filed 2026-08-04 | $63.70B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-29 | $14.45B 10-Q · filed 2026-05-05 | $32.01B derived: sum of 2 quarters · filed 2026-05-05 | $48.66B derived: sum of 3 quarters · filed 2026-05-05 | $63.31B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $17.56B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $34.21B derived: sum of 2 quarters · filed 2026-02-26 | $48.86B derived: sum of 3 quarters · filed 2026-08-04 | $62.58B 10-K · filed 2026-02-26 | ||||
| 2025-09-28 | $16.65B 10-Q · filed 2025-11-04 | $31.31B derived: sum of 2 quarters · filed 2026-08-04 | $45.02B 10-Q · filed 2025-11-04 | $62.78B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-29 | $14.65B 10-Q · filed 2026-08-04 | $28.37B 10-Q · filed 2026-08-04 | $46.13B derived: sum of 3 quarters · filed 2026-08-04 | $63.83B derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-30 | $13.71B 10-Q · filed 2026-05-05 | $31.48B derived: sum of 2 quarters · filed 2026-05-05 | $49.18B derived: sum of 3 quarters · filed 2026-05-05 | $62.46B derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $17.76B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $35.47B derived: sum of 2 quarters · filed 2026-02-26 | $48.75B derived: sum of 3 quarters · filed 2026-02-26 | $63.63B 10-K · filed 2026-02-26 | ||||
| 2024-09-29 | $17.70B 10-Q · filed 2025-11-04 | $30.98B derived: sum of 2 quarters · filed 2025-11-04 | $45.86B 10-Q · filed 2025-11-04 | $60.43B derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $13.28B 10-Q · filed 2025-08-05 | $28.16B 10-Q · filed 2025-08-05 | $42.73B derived: sum of 3 quarters · filed 2026-02-26 | $56.22B derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $14.88B 10-Q · filed 2025-05-05 | $29.45B derived: sum of 2 quarters · filed 2026-02-26 | $42.94B derived: sum of 3 quarters · filed 2026-02-26 | $55.95B derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $14.57B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $28.06B derived: sum of 2 quarters · filed 2026-02-26 | $41.07B derived: sum of 3 quarters · filed 2026-02-26 | $59.55B 10-K · filed 2026-02-26 | $58.50B 10-K · filed 2024-02-22 | |||
| 2023-10-01 | $13.49B 10-Q · filed 2024-11-04 | $13.23B 10-Q · filed 2023-11-08 | $26.50B derived: sum of 2 quarters · filed 2024-11-04 | $44.98B 10-Q · filed 2024-11-04 | $44.25B 10-Q · filed 2023-11-08 | $70.12B derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-07-02 | $13.01B 10-Q · filed 2024-08-05 | $12.73B 10-Q · filed 2023-08-09 | $31.49B 10-Q · filed 2024-08-05 | $31.02B 10-Q · filed 2023-08-09 | $56.63B derived: sum of 3 quarters · filed 2025-02-27 | $79.27B derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-04-02 | $18.49B 10-Q · filed 2024-05-08 | $18.28B 10-Q · filed 2023-05-10 | $43.62B derived: sum of 2 quarters · filed 2025-02-27 | $66.26B derived: sum of 3 quarters · filed 2025-02-27 | $94.00B derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2022-12-31 | $25.14B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $47.77B derived: sum of 2 quarters · filed 2025-02-27 | $75.52B derived: sum of 3 quarters · filed 2025-02-27 | $101.17B 10-K · filed 2025-02-27 | $100.33B 10-K · filed 2023-02-23 | |||
| 2022-10-02 | $22.64B 10-Q · filed 2023-11-08 | $50.38B derived: sum of 2 quarters · filed 2023-11-08 | $76.04B 10-Q · filed 2023-11-08 | |||||
| 2022-07-03 | $27.74B 10-Q · filed 2023-08-09 | $53.40B 10-Q · filed 2023-08-09 | ||||||
| 2022-04-03 | $25.66B 10-Q · filed 2023-05-10 | |||||||
| 2021-12-31 | $81.29B 10-K · filed 2024-02-22 | |||||||
| 2020-12-31 | $41.65B 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |